| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mM * 1 mL in DMSO |
|
||
| 50mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
Levetiracetam 通过增加 HDAC 转录并在启动子上招募辅阻遏物复合物来抑制 O6-甲基鸟嘌呤-DNA-甲基转移酶 (MGMT) 的活性 [1]。多形性胶质母细胞瘤干细胞 (GSC) 对左乙拉西坦 (40 μg/mL) 的替莫唑胺 (250 μM) 处理更加敏感 [1]。左乙拉西坦 (40 μg/mL) 处理 GCSC 会导致 MGMT 表达下调[1]。
|
|---|---|
| 体内研究 (In Vivo) |
左乙拉西坦（10、25 或 50 mg/kg）可抑制缺氧新生儿的脑电图和行为癫痫活动[2]。
|
| 细胞实验 |
细胞活力测定[1]
细胞类型： GCSC 神经球 测试浓度： 40 μg/mL 孵育时间： 48 小时 实验结果：单独使用替莫唑胺 (250 µM) 或左乙拉西坦 (40 μg/mL) 治疗所产生的轻微抗肿瘤作用，当添加替莫唑胺和左乙拉西坦时，会显着增强结合。 蛋白质印迹分析[1] 细胞类型： 多形性胶质母细胞瘤干细胞 (GSC) 测试浓度： 40 μg/ mL 孵育持续时间： 48 小时 实验结果：未处理的 GCSC 中 MGMT 表达水平较高；在单独用替莫唑胺（250 µM）和左乙拉西坦治疗后，该表达略有减少，但在替莫唑胺和左乙拉西坦联合治疗后，该表达显着减少。 |
| 动物实验 |
Animal/Disease Models: Male Long-Evans rats[2]
Doses: 10, 25, or 50 mg/kg Route of Administration: intraperitoneal (ip)injection 60 min before hypoxia. Experimental Results: Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25 mg/ kg and at 50 mg/kg. Anticonvulsant activity was maximal at 50 mg/kg, at which HSs were decreased by 63.6%. |
| 参考文献 |
[1]. Bianca Maria Scicchitano, et al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018 Sep 10;18:136.
[2]. Delia M Talos, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2013 Jan;73(1):24-30. |
| 分子式 |
C8H14N2O2
|
|---|---|
| 分子量 |
170.21
|
| CAS号 |
102767-28-2
|
| 相关CAS号 |
Etiracetam;33996-58-6
|
| SMILES |
O=C(N)[C@H](CC)N1C(CCC1)=O
|
| InChi Key |
HPHUVLMMVZITSG-LURJTMIESA-N
|
| InChi Code |
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
|
| 化学名 |
(S)-2-(2-oxopyrrolidin-1-yl)butanamide
|
| 别名 |
Levetiracetam, UCBL059, UCB L059, UCB-L059, SIB S1, SIBS1, SIB-S1, Keppra, Etiracetam, UCB6474, UCB-6474,
UCB 6474,
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外) |
|
|||
|---|---|---|---|---|
| 溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: Saline: 30 mg/mL Solubility in Formulation 5: 100 mg/mL (587.51 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8751 mL | 29.3755 mL | 58.7510 mL | |
| 5 mM | 1.1750 mL | 5.8751 mL | 11.7502 mL | |
| 10 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06224530 | Not yet recruiting | Drug: Levetiracetam Drug: Placebo |
Psychosis | King's College London | February 2024 | Not Applicable |
| NCT04004702 | Not yet recruiting | Drug: Levetiracetam | Alzheimer Disease | Walter Reed National Military Medical Center |
January 2020 | Phase 2 |
| NCT04317807 | Recruiting | Drug: Levetiracetam Pill Other: Placebo |
Early Psychosis | NYU Langone Health | August 27, 2020 | Phase 2 |
| NCT06067412 | Completed | Drug: Levetiracetam Drug: Phenytoin |
Status Epilepticus | Shaheed Zulfiqar Ali Bhutto Medical University |
August 1, 2022 | Not Applicable |
DNMT2-IN-1
MspI Methyltransferase (MspI )
GpC Methyltransferase (GpC )
EcoRI Methyltransferase (EcoRI Methyltransferase)
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
COA
粤公网安备 44011102003439号